Medications that are combined in a single bottle have the potential benefits of improved efficacy, convenience, and patient compliance, as well as reduced cost. FDA guidelines require the fixed combination to be more efficacious than either drug given alone.
Table 16-12 lists the currently available fixed-combination medications for glaucoma (some are not available in the United States). Before a patient uses the combination drug, each component should be checked for its effect on that patient’s IOP (see BCSC Section 10, Glaucoma).
Excerpted from BCSC 2020-2021 series: Section 2 - Fundamentals and Principles of Ophthalmology. For more information and to purchase the entire series, please visit https://www.aao.org/bcsc.